Search

Your search keyword '"Laplaud, David-Axel"' showing total 287 results

Search Constraints

Start Over You searched for: Author "Laplaud, David-Axel" Remove constraint Author: "Laplaud, David-Axel"
287 results on '"Laplaud, David-Axel"'

Search Results

1. LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France

2. Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study

3. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

4. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: a retrospective observational cohort study

7. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

8. Association between education level and disability progression in patients with multiple sclerosis in France.

9. Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.

10. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

11. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

12. Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study

13. Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis

17. A French cohort for assessing COVID-19 vaccine responses in specific populations

18. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations

19. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data

21. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data

22. An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8+ T cells involved in multiple sclerosis

23. Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data

24. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis

25. Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS

26. Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis

27. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

28. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

29. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome

31. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

32. Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation

34. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis

35. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

37. 84. One-month Humoral Response Following Two Doses of Covid-19 Vaccines in Specific populations – ANRS0001S COV POPART Cohort Study

38. Multiple sclerosis clinical decision support system based on projection to reference datasets

40. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

42. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

44. Gait impairment monitoring in multiple sclerosis using a wearable motion sensor

45. sj-docx-1-msj-10.1177_13524585221139156 – Supplemental material for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

48. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.

49. Semi‐supervised clustering of quaternion time series: Application to gait analysis in multiple sclerosis using motion sensor data.

50. Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients

Catalog

Books, media, physical & digital resources